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METHODS: A retrospective analysis of the 1996 portion
of the Medical Expenditure Panel Survey (MEPS) was
conducted. The MEPS provided data from a nationally
representative sample of 22,601 respondents and data
from respondent’s medical care and health-insurance
providers and employers. Data included medical condi-
tions and employment information comprised of hourly
earnings, hours worked, and disability days. Back pain
patients who incurred disability days were identified us-
ing International Classification of Diseases (ICD-9-CM)
codes determined by an expert panel of physicians and
coders as indicative of back pain and variables denoting
disability days. Indirect costs were calculated for back
pain patients who missed workdays using the human
capital approach. Sample estimates were weighted and
projected to the population and 95 percent confidence in-
tervals for estimates were calculated using the Taylor ex-
pansion method.
RESULTS: Total indirect costs for back pain patients
who missed workdays were $18,533,583,620. Mean in-
direct costs were $4586 per back pain patient who
missed workdays (95% CI  $3852 to $5321). Relative
to the entire population, the mean indirect costs were
$68.92 per person.
CONCLUSIONS: With losses in productivity greater than
$18.5 billion, indirect costs significantly contribute to the
total cost of back pain. The indirect costs of back pain to
labor underscore the need to prevent back injury thereby
promoting employee health and maintaining productivity.
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OBJECTIVES: To assess the influence of depression, de-
mentia and disease severity on the health-related quality
of life in Parkinson’s disease (PD).
METHODS: Health-related quality of life was assessed
in 91 patients with PD (male: 62; female: 29; mean age:
67  9) using the Parkinson’s disease questionnaire
(PDQ-39) and the Parkinson’s disease Quality of life
questionnaire (PDQL). Dementia was evaluated by using
the MMSE and depression was rated with the Beck’s De-
pression Inventory (BDI). Disease severity and motor dys-
function were recorded with the Hoehn and Yahr scale
and the UPDRS II-IV. Pearson’s correlation coefficient
was used to calculate correlation scores.
RESULTS: Both specific disease QoL rating scales corre-
lated with depressive symptoms (r  0.73, p  .0001).
UPDRS III (r  0.69, p  .0001) and HY stage (r  0.59,
p  .001) also correlated with decreased QoL. However,
motor fluctuations and dyskinesias had a minor impact
on QoL (r  0.40, p  .001). Dementia or cognitive im-
pairment had a minor correlation with QoL (r  0.30, p 
.001).
CONCLUSIONS: We found a high correlation between
QoL and depression by using PDQ-39 and PDQL. In
contrast, a minor correlation was observed between
MMSE scores and health-related QoL. Treating depres-
sive symptoms in PD patients may considerably improve
their quality of life.
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OBJECTIVE: 25% to 30% of patients with Parkinson’s
disease treated with levodopa present motor complica-
tions after three years. The health-care consumption by
patients with these symptoms is roughly twice as high as
the costs for patients without them. A clinical trial com-
paring cabergoline (with the possibility if adding levodopa
if needed) to levodopa has shown that the use of caber-
goline delays the onset of motor complications. The pur-
pose of this study is to compare the cost-effectiveness of
the two treatment strategies in a Swedish setting.
METHODS: A Markov model was constructed with
states based on the Hoehn and Yahr (HY) stages with an
additional stage for patients with complications. Transi-
tion probabilities between the HY stages were calculated
from the clinical trial data using ordered probit regres-
sion, while the probability of developing complications
was based on the frequency of this event at each time
point in the trial. Direct costs were derived from a Swed-
ish observational study. Years-of-complications-avoided
was used as the measure of effectiveness in this analysis.
RESULTS: The incremental cost-effectiveness ratio for
cabergoline was 4000 USD per year of motor complica-
tions avoided. Inclusion of indirect costs would influence
the results in younger patients. The literature suggests
that the costs of indirect care would decrease the cost-ef-
fectiveness ratio, so that the number reported here may
represent an overestimate of the total cost of preventing
motor complications.
CONCLUSION: Based on our data, Cabergoline was
found to represent a cost-effective means for reducing the
impact of motor dysfunction if the willingness to pay ex-
ceeds 4000 USD per year of motor complications avoided.
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